Cuprina and Singapore Biowaste Solutions Enter MOU to Integrate Medical Waste Management Technologies
SINGAPORE, Oct. 27, 2025 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company specializing in the development and marketing of products for chronic wounds, infertility, and cosmeceuticals, announced today the signing of a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a company dedicated to the treatment and disposal of biomedical waste. This agreement is aimed at exploring the integration of Cuprina’s medical waste recycling technology into SBS’s existing waste management facility located in Singapore.
The objective of this collaboration is to establish an integrated process designed to further diminish reliance on incineration and landfilling, boost recycling effectiveness, generate new income streams from recovered materials, and position both companies and Singapore as frontrunners in environmentally sound waste management.
In accordance with the MOU, Cuprina will supply technical expertise, training, and assistance for this exploratory phase, which will encompass a feasibility study and a pilot program at SBS’s facility. During this period, Cuprina will utilize its exclusive licensing rights in Southeast Asia for a high-temperature steam process, known as autoclaving, to sterilize, decontaminate, and transform plastic-based medical waste into valuable resins. This technology represents the first of its kind developed under the guidance of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), which collaboratively fund worldwide environmental initiatives.
As stipulated by the MOU, SBS will provide operational data, facility access, and regulatory support necessary to facilitate the integration of the companies’ combined waste recycling process with Singapore’s environmental benchmarks, and to ensure compliance with Singaporean regulatory bodies such as the National Environment Agency and the Ministry of Health.
Together, the companies intend to develop revenue-sharing models for the integrated process and investigate opportunities for expanding the technology across Southeast Asia;
“We are enthusiastic about signing this MOU, which signifies the initial prospective commercialization of our recently licensed medical waste recycling technology for Cuprina,” stated David Quek Yong Qi, CEO of Cuprina. “We are confident that this technology, refined and validated over 20 years with UNIDO and GEF, will seamlessly integrate with SBS’s waste management procedures. We eagerly anticipate working with SBS on our pilot program and finalizing a definitive agreement in the near future.”
Mr. Quek expressed his belief that the integrated recycling technology developed by the companies could secure all requisite Singaporean regulatory approvals and commence operations by the close of 2026.
Selva Kumar, Managing Director of SBS, added, “We are delighted to partner with Cuprina on this innovative approach to waste management. We believe that incorporating their technology into our processes will aid us in meeting evolving environmental regulations and contribute to a circular economy within Singapore and beyond.”
About Cuprina Holdings (Cayman) Limited
We are a biomedical and biotechnology company based in Singapore, dedicated to the development and commercialization of innovative products for chronic wound management, as well as participating in the health and beauty sectors. Our proficiency in biomedical research allows us to identify and employ materials derived from natural sources to create wound care products in the form of medical devices that adhere to international standards.
For more information, please visit
About Singapore Biowaste Solutions Pte Ltd
Singapore Biowaste Solutions Pte Ltd is recognized as Singapore’s premier provider for biomedical waste disposal and management. The company offers advanced technologies, a highly skilled team of operational experts, modern facilities, and a steadfast commitment to fulfilling the requirements of its clients.
FORWARD-LOOKING STATEMENTS
This press release contains certain statements regarding future expectations, plans, and prospects, along with any other statements not representing historical facts, which may be classified as “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, those related to anticipated trading commencement and closing dates. The terms “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are utilized to identify forward-looking statements, though not all such statements include these identifying words. Actual outcomes may differ significantly from those suggested by such forward-looking statements due to various crucial factors, including: the uncertainties associated with market conditions and the completion of the public offering on the expected terms or at all, as well as other considerations detailed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are advised against placing undue reliance on any forward-looking statements in this press release. Any forward-looking statements presented in this press release are valid only as of the date hereof, and Cuprina Holdings (Cayman) Limited explicitly disclaims any obligation to update any forward-looking statement, whether arising from new information, future events, or otherwise, except as mandated by law.
Cuprina Holdings (Cayman) Limited Investor Contact:
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:
